Benign Prostatic Hyperplasia (BPH) Drugs-Global Market Status and Trend Report 2013-2023
Report Summary
Benign Prostatic Hyperplasia (BPH) Drugs-Global Market Status and Trend Report 2013-2023 offers a comprehensive analysis on Benign Prostatic Hyperplasia (BPH) Drugs industry, standing on the readers? perspective, delivering detailed market data and penetrating insights. No matter the client is industry insider, potential entrant or investor, the report will provides useful data and information. Key questions answered by this report include:
Worldwide and Regional Market Size of Benign Prostatic Hyperplasia (BPH) Drugs 2013-2017, and development forecast 2018-2023
Main manufacturers/suppliers of Benign Prostatic Hyperplasia (BPH) Drugs worldwide, with company and product introduction, position in the Benign Prostatic Hyperplasia (BPH) Drugs market
Market status and development trend of Benign Prostatic Hyperplasia (BPH) Drugs by types and applications
Cost and profit status of Benign Prostatic Hyperplasia (BPH) Drugs, and marketing status
Market growth drivers and challenges
The report segments the global Benign Prostatic Hyperplasia (BPH) Drugs market as:
Global Benign Prostatic Hyperplasia (BPH) Drugs Market: Regional Segment Analysis (Regional Production Volume, Consumption Volume, Revenue and Growth Rate 2013-2023):
North America
Europe
China
Japan
Rest APAC
Latin America
Global Benign Prostatic Hyperplasia (BPH) Drugs Market: Type Segment Analysis (Consumption Volume, Average Price, Revenue, Market Share and Trend 2013-2023):
Alpha-blocker
Phosphodiesterase Type-5 Inhibitors
5-alpha-Reductase Inhibitors
Global Benign Prostatic Hyperplasia (BPH) Drugs Market: Application Segment Analysis (Consumption Volume and Market Share 2013-2023; Downstream Customers and Market Analysis)
Hospitals
Clinics
Others
Global Benign Prostatic Hyperplasia (BPH) Drugs Market: Manufacturers Segment Analysis (Company and Product introduction, Benign Prostatic Hyperplasia (BPH) Drugs Sales Volume, Revenue, Price and Gross Margin):
Astellas Pharma
Eli Lilly
GlaxoSmithKline
Sanofi
ADC Therapeutics
Bayer HealthCare
Bristol-Myers Squibb
Valeant Pharmaceuticals
Endo Pharmaceuticals
Foresee Pharmaceuticals
Madrigal Pharmaceuticals
Merck
Novartis
Spectrum Pharmaceuticals
Takeda Pharmaceuticals
Teva
Advaxis
ANI Pharmaceuticals
BHR Pharma
In a word, the report provides detailed statistics and analysis on the state of the industry; and is a valuable source of guidance and direction for companies and individuals interested in the market.
Benign Prostatic Hyperplasia (BPH) Drugs-Global Market Status and Trend Report 2013-2023 offers a comprehensive analysis on Benign Prostatic Hyperplasia (BPH) Drugs industry, standing on the readers? perspective, delivering detailed market data and penetrating insights. No matter the client is industry insider, potential entrant or investor, the report will provides useful data and information. Key questions answered by this report include:
Worldwide and Regional Market Size of Benign Prostatic Hyperplasia (BPH) Drugs 2013-2017, and development forecast 2018-2023
Main manufacturers/suppliers of Benign Prostatic Hyperplasia (BPH) Drugs worldwide, with company and product introduction, position in the Benign Prostatic Hyperplasia (BPH) Drugs market
Market status and development trend of Benign Prostatic Hyperplasia (BPH) Drugs by types and applications
Cost and profit status of Benign Prostatic Hyperplasia (BPH) Drugs, and marketing status
Market growth drivers and challenges
The report segments the global Benign Prostatic Hyperplasia (BPH) Drugs market as:
Global Benign Prostatic Hyperplasia (BPH) Drugs Market: Regional Segment Analysis (Regional Production Volume, Consumption Volume, Revenue and Growth Rate 2013-2023):
North America
Europe
China
Japan
Rest APAC
Latin America
Global Benign Prostatic Hyperplasia (BPH) Drugs Market: Type Segment Analysis (Consumption Volume, Average Price, Revenue, Market Share and Trend 2013-2023):
Alpha-blocker
Phosphodiesterase Type-5 Inhibitors
5-alpha-Reductase Inhibitors
Global Benign Prostatic Hyperplasia (BPH) Drugs Market: Application Segment Analysis (Consumption Volume and Market Share 2013-2023; Downstream Customers and Market Analysis)
Hospitals
Clinics
Others
Global Benign Prostatic Hyperplasia (BPH) Drugs Market: Manufacturers Segment Analysis (Company and Product introduction, Benign Prostatic Hyperplasia (BPH) Drugs Sales Volume, Revenue, Price and Gross Margin):
Astellas Pharma
Eli Lilly
GlaxoSmithKline
Sanofi
ADC Therapeutics
Bayer HealthCare
Bristol-Myers Squibb
Valeant Pharmaceuticals
Endo Pharmaceuticals
Foresee Pharmaceuticals
Madrigal Pharmaceuticals
Merck
Novartis
Spectrum Pharmaceuticals
Takeda Pharmaceuticals
Teva
Advaxis
ANI Pharmaceuticals
BHR Pharma
In a word, the report provides detailed statistics and analysis on the state of the industry; and is a valuable source of guidance and direction for companies and individuals interested in the market.
CHAPTER 1 OVERVIEW OF BENIGN PROSTATIC HYPERPLASIA (BPH) DRUGS
1.1 Definition of Benign Prostatic Hyperplasia (BPH) Drugs in This Report
1.2 Commercial Types of Benign Prostatic Hyperplasia (BPH) Drugs
1.2.1 Alpha-blocker
1.2.2 Phosphodiesterase Type-5 Inhibitors
1.2.3 5-alpha-Reductase Inhibitors
1.3 Downstream Application of Benign Prostatic Hyperplasia (BPH) Drugs
1.3.1 Hospitals
1.3.2 Clinics
1.3.3 Others
1.4 Development History of Benign Prostatic Hyperplasia (BPH) Drugs
1.5 Market Status and Trend of Benign Prostatic Hyperplasia (BPH) Drugs 2013-2023
1.5.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Market Status and Trend 2013-2023
1.5.2 Regional Benign Prostatic Hyperplasia (BPH) Drugs Market Status and Trend 2013-2023
CHAPTER 2 GLOBAL MARKET STATUS AND FORECAST BY REGIONS
2.1 Market Development of Benign Prostatic Hyperplasia (BPH) Drugs 2013-2017
2.2 Sales Market of Benign Prostatic Hyperplasia (BPH) Drugs by Regions
2.2.1 Sales Volume of Benign Prostatic Hyperplasia (BPH) Drugs by Regions
2.2.2 Sales Value of Benign Prostatic Hyperplasia (BPH) Drugs by Regions
2.3 Production Market of Benign Prostatic Hyperplasia (BPH) Drugs by Regions
2.4 Global Market Forecast of Benign Prostatic Hyperplasia (BPH) Drugs 2018-2023
2.4.1 Global Market Forecast of Benign Prostatic Hyperplasia (BPH) Drugs 2018-2023
2.4.2 Market Forecast of Benign Prostatic Hyperplasia (BPH) Drugs by Regions 2018-2023
CHAPTER 3 GLOBAL MARKET STATUS AND FORECAST BY TYPES
3.1 Sales Volume of Benign Prostatic Hyperplasia (BPH) Drugs by Types
3.2 Sales Value of Benign Prostatic Hyperplasia (BPH) Drugs by Types
3.3 Market Forecast of Benign Prostatic Hyperplasia (BPH) Drugs by Types
CHAPTER 4 GLOBAL MARKET STATUS AND FORECAST BY DOWNSTREAM INDUSTRY
4.1 Global Sales Volume of Benign Prostatic Hyperplasia (BPH) Drugs by Downstream Industry
4.2 Global Market Forecast of Benign Prostatic Hyperplasia (BPH) Drugs by Downstream Industry
CHAPTER 5 NORTH AMERICA MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY
5.1 North America Benign Prostatic Hyperplasia (BPH) Drugs Market Status by Countries
5.1.1 North America Benign Prostatic Hyperplasia (BPH) Drugs Sales by Countries (2013-2017)
5.1.2 North America Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Countries (2013-2017)
5.1.3 United States Benign Prostatic Hyperplasia (BPH) Drugs Market Status (2013-2017)
5.1.4 Canada Benign Prostatic Hyperplasia (BPH) Drugs Market Status (2013-2017)
5.1.5 Mexico Benign Prostatic Hyperplasia (BPH) Drugs Market Status (2013-2017)
5.2 North America Benign Prostatic Hyperplasia (BPH) Drugs Market Status by Manufacturers
5.3 North America Benign Prostatic Hyperplasia (BPH) Drugs Market Status by Type (2013-2017)
5.3.1 North America Benign Prostatic Hyperplasia (BPH) Drugs Sales by Type (2013-2017)
5.3.2 North America Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Type (2013-2017)
5.4 North America Benign Prostatic Hyperplasia (BPH) Drugs Market Status by Downstream Industry (2013-2017)
CHAPTER 6 EUROPE MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY
6.1 Europe Benign Prostatic Hyperplasia (BPH) Drugs Market Status by Countries
6.1.1 Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales by Countries (2013-2017)
6.1.2 Europe Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Countries (2013-2017)
6.1.3 Germany Benign Prostatic Hyperplasia (BPH) Drugs Market Status (2013-2017)
6.1.4 UK Benign Prostatic Hyperplasia (BPH) Drugs Market Status (2013-2017)
6.1.5 France Benign Prostatic Hyperplasia (BPH) Drugs Market Status (2013-2017)
6.1.6 Italy Benign Prostatic Hyperplasia (BPH) Drugs Market Status (2013-2017)
6.1.7 Russia Benign Prostatic Hyperplasia (BPH) Drugs Market Status (2013-2017)
6.1.8 Spain Benign Prostatic Hyperplasia (BPH) Drugs Market Status (2013-2017)
6.1.9 Benelux Benign Prostatic Hyperplasia (BPH) Drugs Market Status (2013-2017)
6.2 Europe Benign Prostatic Hyperplasia (BPH) Drugs Market Status by Manufacturers
6.3 Europe Benign Prostatic Hyperplasia (BPH) Drugs Market Status by Type (2013-2017)
6.3.1 Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales by Type (2013-2017)
6.3.2 Europe Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Type (2013-2017)
6.4 Europe Benign Prostatic Hyperplasia (BPH) Drugs Market Status by Downstream Industry (2013-2017)
CHAPTER 7 ASIA PACIFIC MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY
7.1 Asia Pacific Benign Prostatic Hyperplasia (BPH) Drugs Market Status by Countries
7.1.1 Asia Pacific Benign Prostatic Hyperplasia (BPH) Drugs Sales by Countries (2013-2017)
7.1.2 Asia Pacific Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Countries (2013-2017)
7.1.3 China Benign Prostatic Hyperplasia (BPH) Drugs Market Status (2013-2017)
7.1.4 Japan Benign Prostatic Hyperplasia (BPH) Drugs Market Status (2013-2017)
7.1.5 India Benign Prostatic Hyperplasia (BPH) Drugs Market Status (2013-2017)
7.1.6 Southeast Asia Benign Prostatic Hyperplasia (BPH) Drugs Market Status (2013-2017)
7.1.7 Australia Benign Prostatic Hyperplasia (BPH) Drugs Market Status (2013-2017)
7.2 Asia Pacific Benign Prostatic Hyperplasia (BPH) Drugs Market Status by Manufacturers
7.3 Asia Pacific Benign Prostatic Hyperplasia (BPH) Drugs Market Status by Type (2013-2017)
7.3.1 Asia Pacific Benign Prostatic Hyperplasia (BPH) Drugs Sales by Type (2013-2017)
7.3.2 Asia Pacific Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Type (2013-2017)
7.4 Asia Pacific Benign Prostatic Hyperplasia (BPH) Drugs Market Status by Downstream Industry (2013-2017)
CHAPTER 8 LATIN AMERICA MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY
8.1 Latin America Benign Prostatic Hyperplasia (BPH) Drugs Market Status by Countries
8.1.1 Latin America Benign Prostatic Hyperplasia (BPH) Drugs Sales by Countries (2013-2017)
8.1.2 Latin America Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Countries (2013-2017)
8.1.3 Brazil Benign Prostatic Hyperplasia (BPH) Drugs Market Status (2013-2017)
8.1.4 Argentina Benign Prostatic Hyperplasia (BPH) Drugs Market Status (2013-2017)
8.1.5 Colombia Benign Prostatic Hyperplasia (BPH) Drugs Market Status (2013-2017)
8.2 Latin America Benign Prostatic Hyperplasia (BPH) Drugs Market Status by Manufacturers
8.3 Latin America Benign Prostatic Hyperplasia (BPH) Drugs Market Status by Type (2013-2017)
8.3.1 Latin America Benign Prostatic Hyperplasia (BPH) Drugs Sales by Type (2013-2017)
8.3.2 Latin America Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Type (2013-2017)
8.4 Latin America Benign Prostatic Hyperplasia (BPH) Drugs Market Status by Downstream Industry (2013-2017)
CHAPTER 9 MIDDLE EAST AND AFRICA MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY
9.1 Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Market Status by Countries
9.1.1 Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales by Countries (2013-2017)
9.1.2 Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Countries (2013-2017)
9.1.3 Middle East Benign Prostatic Hyperplasia (BPH) Drugs Market Status (2013-2017)
9.1.4 Africa Benign Prostatic Hyperplasia (BPH) Drugs Market Status (2013-2017)
9.2 Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Market Status by Manufacturers
9.3 Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Market Status by Type (2013-2017)
9.3.1 Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales by Type (2013-2017)
9.3.2 Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Type (2013-2017)
9.4 Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Market Status by Downstream Industry (2013-2017)
CHAPTER 10 MARKET DRIVING FACTOR ANALYSIS OF BENIGN PROSTATIC HYPERPLASIA (BPH) DRUGS
10.1 Global Economy Situation and Trend Overview
10.2 Benign Prostatic Hyperplasia (BPH) Drugs Downstream Industry Situation and Trend Overview
CHAPTER 11 BENIGN PROSTATIC HYPERPLASIA (BPH) DRUGS MARKET COMPETITION STATUS BY MAJOR MANUFACTURERS
11.1 Production Volume of Benign Prostatic Hyperplasia (BPH) Drugs by Major Manufacturers
11.2 Production Value of Benign Prostatic Hyperplasia (BPH) Drugs by Major Manufacturers
11.3 Basic Information of Benign Prostatic Hyperplasia (BPH) Drugs by Major Manufacturers
11.3.1 Headquarters Location and Established Time of Benign Prostatic Hyperplasia (BPH) Drugs Major Manufacturer
11.3.2 Employees and Revenue Level of Benign Prostatic Hyperplasia (BPH) Drugs Major Manufacturer
11.4 Market Competition News and Trend
11.4.1 Merger, Consolidation or Acquisition News
11.4.2 Investment or Disinvestment News
11.4.3 New Product Development and Launch
CHAPTER 12 BENIGN PROSTATIC HYPERPLASIA (BPH) DRUGS MAJOR MANUFACTURERS INTRODUCTION AND MARKET DATA
12.1 Astellas Pharma
12.1.1 Company profile
12.1.2 Representative Benign Prostatic Hyperplasia (BPH) Drugs Product
12.1.3 Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue, Price and Gross Margin of Astellas Pharma
12.2 Eli Lilly
12.2.1 Company profile
12.2.2 Representative Benign Prostatic Hyperplasia (BPH) Drugs Product
12.2.3 Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue, Price and Gross Margin of Eli Lilly
12.3 GlaxoSmithKline
12.3.1 Company profile
12.3.2 Representative Benign Prostatic Hyperplasia (BPH) Drugs Product
12.3.3 Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue, Price and Gross Margin of GlaxoSmithKline
12.4 Sanofi
12.4.1 Company profile
12.4.2 Representative Benign Prostatic Hyperplasia (BPH) Drugs Product
12.4.3 Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue, Price and Gross Margin of Sanofi
12.5 ADC Therapeutics
12.5.1 Company profile
12.5.2 Representative Benign Prostatic Hyperplasia (BPH) Drugs Product
12.5.3 Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue, Price and Gross Margin of ADC Therapeutics
12.6 Bayer HealthCare
12.6.1 Company profile
12.6.2 Representative Benign Prostatic Hyperplasia (BPH) Drugs Product
12.6.3 Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue, Price and Gross Margin of Bayer HealthCare
12.7 Bristol-Myers Squibb
12.7.1 Company profile
12.7.2 Representative Benign Prostatic Hyperplasia (BPH) Drugs Product
12.7.3 Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue, Price and Gross Margin of Bristol-Myers Squibb
12.8 Valeant Pharmaceuticals
12.8.1 Company profile
12.8.2 Representative Benign Prostatic Hyperplasia (BPH) Drugs Product
12.8.3 Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue, Price and Gross Margin of Valeant Pharmaceuticals
12.9 Endo Pharmaceuticals
12.9.1 Company profile
12.9.2 Representative Benign Prostatic Hyperplasia (BPH) Drugs Product
12.9.3 Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue, Price and Gross Margin of Endo Pharmaceuticals
12.10 Foresee Pharmaceuticals
12.10.1 Company profile
12.10.2 Representative Benign Prostatic Hyperplasia (BPH) Drugs Product
12.10.3 Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue, Price and Gross Margin of Foresee Pharmaceuticals
12.11 Madrigal Pharmaceuticals
12.11.1 Company profile
12.11.2 Representative Benign Prostatic Hyperplasia (BPH) Drugs Product
12.11.3 Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue, Price and Gross Margin of Madrigal Pharmaceuticals
12.12 Merck
12.12.1 Company profile
12.12.2 Representative Benign Prostatic Hyperplasia (BPH) Drugs Product
12.12.3 Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue, Price and Gross Margin of Merck
12.13 Novartis
12.13.1 Company profile
12.13.2 Representative Benign Prostatic Hyperplasia (BPH) Drugs Product
12.13.3 Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue, Price and Gross Margin of Novartis
12.14 Spectrum Pharmaceuticals
12.14.1 Company profile
12.14.2 Representative Benign Prostatic Hyperplasia (BPH) Drugs Product
12.14.3 Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue, Price and Gross Margin of Spectrum Pharmaceuticals
12.15 Takeda Pharmaceuticals
12.15.1 Company profile
12.15.2 Representative Benign Prostatic Hyperplasia (BPH) Drugs Product
12.15.3 Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue, Price and Gross Margin of Takeda Pharmaceuticals
12.16 Teva
12.17 Advaxis
12.18 ANI Pharmaceuticals
12.19 BHR Pharma
CHAPTER 13 UPSTREAM AND DOWNSTREAM MARKET ANALYSIS OF BENIGN PROSTATIC HYPERPLASIA (BPH) DRUGS
13.1 Industry Chain of Benign Prostatic Hyperplasia (BPH) Drugs
13.2 Upstream Market and Representative Companies Analysis
13.3 Downstream Market and Representative Companies Analysis
CHAPTER 14 COST AND GROSS MARGIN ANALYSIS OF BENIGN PROSTATIC HYPERPLASIA (BPH) DRUGS
14.1 Cost Structure Analysis of Benign Prostatic Hyperplasia (BPH) Drugs
14.2 Raw Materials Cost Analysis of Benign Prostatic Hyperplasia (BPH) Drugs
14.3 Labor Cost Analysis of Benign Prostatic Hyperplasia (BPH) Drugs
14.4 Manufacturing Expenses Analysis of Benign Prostatic Hyperplasia (BPH) Drugs
CHAPTER 15 REPORT CONCLUSION
CHAPTER 16 RESEARCH METHODOLOGY AND REFERENCE
16.1 Methodology/Research Approach
16.1.1 Research Programs/Design
16.1.2 Market Size Estimation
16.1.3 Market Breakdown and Data Triangulation
16.2 Data Source
16.2.1 Secondary Sources
16.2.2 Primary Sources
16.3 Reference
1.1 Definition of Benign Prostatic Hyperplasia (BPH) Drugs in This Report
1.2 Commercial Types of Benign Prostatic Hyperplasia (BPH) Drugs
1.2.1 Alpha-blocker
1.2.2 Phosphodiesterase Type-5 Inhibitors
1.2.3 5-alpha-Reductase Inhibitors
1.3 Downstream Application of Benign Prostatic Hyperplasia (BPH) Drugs
1.3.1 Hospitals
1.3.2 Clinics
1.3.3 Others
1.4 Development History of Benign Prostatic Hyperplasia (BPH) Drugs
1.5 Market Status and Trend of Benign Prostatic Hyperplasia (BPH) Drugs 2013-2023
1.5.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Market Status and Trend 2013-2023
1.5.2 Regional Benign Prostatic Hyperplasia (BPH) Drugs Market Status and Trend 2013-2023
CHAPTER 2 GLOBAL MARKET STATUS AND FORECAST BY REGIONS
2.1 Market Development of Benign Prostatic Hyperplasia (BPH) Drugs 2013-2017
2.2 Sales Market of Benign Prostatic Hyperplasia (BPH) Drugs by Regions
2.2.1 Sales Volume of Benign Prostatic Hyperplasia (BPH) Drugs by Regions
2.2.2 Sales Value of Benign Prostatic Hyperplasia (BPH) Drugs by Regions
2.3 Production Market of Benign Prostatic Hyperplasia (BPH) Drugs by Regions
2.4 Global Market Forecast of Benign Prostatic Hyperplasia (BPH) Drugs 2018-2023
2.4.1 Global Market Forecast of Benign Prostatic Hyperplasia (BPH) Drugs 2018-2023
2.4.2 Market Forecast of Benign Prostatic Hyperplasia (BPH) Drugs by Regions 2018-2023
CHAPTER 3 GLOBAL MARKET STATUS AND FORECAST BY TYPES
3.1 Sales Volume of Benign Prostatic Hyperplasia (BPH) Drugs by Types
3.2 Sales Value of Benign Prostatic Hyperplasia (BPH) Drugs by Types
3.3 Market Forecast of Benign Prostatic Hyperplasia (BPH) Drugs by Types
CHAPTER 4 GLOBAL MARKET STATUS AND FORECAST BY DOWNSTREAM INDUSTRY
4.1 Global Sales Volume of Benign Prostatic Hyperplasia (BPH) Drugs by Downstream Industry
4.2 Global Market Forecast of Benign Prostatic Hyperplasia (BPH) Drugs by Downstream Industry
CHAPTER 5 NORTH AMERICA MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY
5.1 North America Benign Prostatic Hyperplasia (BPH) Drugs Market Status by Countries
5.1.1 North America Benign Prostatic Hyperplasia (BPH) Drugs Sales by Countries (2013-2017)
5.1.2 North America Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Countries (2013-2017)
5.1.3 United States Benign Prostatic Hyperplasia (BPH) Drugs Market Status (2013-2017)
5.1.4 Canada Benign Prostatic Hyperplasia (BPH) Drugs Market Status (2013-2017)
5.1.5 Mexico Benign Prostatic Hyperplasia (BPH) Drugs Market Status (2013-2017)
5.2 North America Benign Prostatic Hyperplasia (BPH) Drugs Market Status by Manufacturers
5.3 North America Benign Prostatic Hyperplasia (BPH) Drugs Market Status by Type (2013-2017)
5.3.1 North America Benign Prostatic Hyperplasia (BPH) Drugs Sales by Type (2013-2017)
5.3.2 North America Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Type (2013-2017)
5.4 North America Benign Prostatic Hyperplasia (BPH) Drugs Market Status by Downstream Industry (2013-2017)
CHAPTER 6 EUROPE MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY
6.1 Europe Benign Prostatic Hyperplasia (BPH) Drugs Market Status by Countries
6.1.1 Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales by Countries (2013-2017)
6.1.2 Europe Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Countries (2013-2017)
6.1.3 Germany Benign Prostatic Hyperplasia (BPH) Drugs Market Status (2013-2017)
6.1.4 UK Benign Prostatic Hyperplasia (BPH) Drugs Market Status (2013-2017)
6.1.5 France Benign Prostatic Hyperplasia (BPH) Drugs Market Status (2013-2017)
6.1.6 Italy Benign Prostatic Hyperplasia (BPH) Drugs Market Status (2013-2017)
6.1.7 Russia Benign Prostatic Hyperplasia (BPH) Drugs Market Status (2013-2017)
6.1.8 Spain Benign Prostatic Hyperplasia (BPH) Drugs Market Status (2013-2017)
6.1.9 Benelux Benign Prostatic Hyperplasia (BPH) Drugs Market Status (2013-2017)
6.2 Europe Benign Prostatic Hyperplasia (BPH) Drugs Market Status by Manufacturers
6.3 Europe Benign Prostatic Hyperplasia (BPH) Drugs Market Status by Type (2013-2017)
6.3.1 Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales by Type (2013-2017)
6.3.2 Europe Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Type (2013-2017)
6.4 Europe Benign Prostatic Hyperplasia (BPH) Drugs Market Status by Downstream Industry (2013-2017)
CHAPTER 7 ASIA PACIFIC MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY
7.1 Asia Pacific Benign Prostatic Hyperplasia (BPH) Drugs Market Status by Countries
7.1.1 Asia Pacific Benign Prostatic Hyperplasia (BPH) Drugs Sales by Countries (2013-2017)
7.1.2 Asia Pacific Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Countries (2013-2017)
7.1.3 China Benign Prostatic Hyperplasia (BPH) Drugs Market Status (2013-2017)
7.1.4 Japan Benign Prostatic Hyperplasia (BPH) Drugs Market Status (2013-2017)
7.1.5 India Benign Prostatic Hyperplasia (BPH) Drugs Market Status (2013-2017)
7.1.6 Southeast Asia Benign Prostatic Hyperplasia (BPH) Drugs Market Status (2013-2017)
7.1.7 Australia Benign Prostatic Hyperplasia (BPH) Drugs Market Status (2013-2017)
7.2 Asia Pacific Benign Prostatic Hyperplasia (BPH) Drugs Market Status by Manufacturers
7.3 Asia Pacific Benign Prostatic Hyperplasia (BPH) Drugs Market Status by Type (2013-2017)
7.3.1 Asia Pacific Benign Prostatic Hyperplasia (BPH) Drugs Sales by Type (2013-2017)
7.3.2 Asia Pacific Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Type (2013-2017)
7.4 Asia Pacific Benign Prostatic Hyperplasia (BPH) Drugs Market Status by Downstream Industry (2013-2017)
CHAPTER 8 LATIN AMERICA MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY
8.1 Latin America Benign Prostatic Hyperplasia (BPH) Drugs Market Status by Countries
8.1.1 Latin America Benign Prostatic Hyperplasia (BPH) Drugs Sales by Countries (2013-2017)
8.1.2 Latin America Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Countries (2013-2017)
8.1.3 Brazil Benign Prostatic Hyperplasia (BPH) Drugs Market Status (2013-2017)
8.1.4 Argentina Benign Prostatic Hyperplasia (BPH) Drugs Market Status (2013-2017)
8.1.5 Colombia Benign Prostatic Hyperplasia (BPH) Drugs Market Status (2013-2017)
8.2 Latin America Benign Prostatic Hyperplasia (BPH) Drugs Market Status by Manufacturers
8.3 Latin America Benign Prostatic Hyperplasia (BPH) Drugs Market Status by Type (2013-2017)
8.3.1 Latin America Benign Prostatic Hyperplasia (BPH) Drugs Sales by Type (2013-2017)
8.3.2 Latin America Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Type (2013-2017)
8.4 Latin America Benign Prostatic Hyperplasia (BPH) Drugs Market Status by Downstream Industry (2013-2017)
CHAPTER 9 MIDDLE EAST AND AFRICA MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY
9.1 Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Market Status by Countries
9.1.1 Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales by Countries (2013-2017)
9.1.2 Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Countries (2013-2017)
9.1.3 Middle East Benign Prostatic Hyperplasia (BPH) Drugs Market Status (2013-2017)
9.1.4 Africa Benign Prostatic Hyperplasia (BPH) Drugs Market Status (2013-2017)
9.2 Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Market Status by Manufacturers
9.3 Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Market Status by Type (2013-2017)
9.3.1 Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales by Type (2013-2017)
9.3.2 Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Type (2013-2017)
9.4 Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Market Status by Downstream Industry (2013-2017)
CHAPTER 10 MARKET DRIVING FACTOR ANALYSIS OF BENIGN PROSTATIC HYPERPLASIA (BPH) DRUGS
10.1 Global Economy Situation and Trend Overview
10.2 Benign Prostatic Hyperplasia (BPH) Drugs Downstream Industry Situation and Trend Overview
CHAPTER 11 BENIGN PROSTATIC HYPERPLASIA (BPH) DRUGS MARKET COMPETITION STATUS BY MAJOR MANUFACTURERS
11.1 Production Volume of Benign Prostatic Hyperplasia (BPH) Drugs by Major Manufacturers
11.2 Production Value of Benign Prostatic Hyperplasia (BPH) Drugs by Major Manufacturers
11.3 Basic Information of Benign Prostatic Hyperplasia (BPH) Drugs by Major Manufacturers
11.3.1 Headquarters Location and Established Time of Benign Prostatic Hyperplasia (BPH) Drugs Major Manufacturer
11.3.2 Employees and Revenue Level of Benign Prostatic Hyperplasia (BPH) Drugs Major Manufacturer
11.4 Market Competition News and Trend
11.4.1 Merger, Consolidation or Acquisition News
11.4.2 Investment or Disinvestment News
11.4.3 New Product Development and Launch
CHAPTER 12 BENIGN PROSTATIC HYPERPLASIA (BPH) DRUGS MAJOR MANUFACTURERS INTRODUCTION AND MARKET DATA
12.1 Astellas Pharma
12.1.1 Company profile
12.1.2 Representative Benign Prostatic Hyperplasia (BPH) Drugs Product
12.1.3 Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue, Price and Gross Margin of Astellas Pharma
12.2 Eli Lilly
12.2.1 Company profile
12.2.2 Representative Benign Prostatic Hyperplasia (BPH) Drugs Product
12.2.3 Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue, Price and Gross Margin of Eli Lilly
12.3 GlaxoSmithKline
12.3.1 Company profile
12.3.2 Representative Benign Prostatic Hyperplasia (BPH) Drugs Product
12.3.3 Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue, Price and Gross Margin of GlaxoSmithKline
12.4 Sanofi
12.4.1 Company profile
12.4.2 Representative Benign Prostatic Hyperplasia (BPH) Drugs Product
12.4.3 Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue, Price and Gross Margin of Sanofi
12.5 ADC Therapeutics
12.5.1 Company profile
12.5.2 Representative Benign Prostatic Hyperplasia (BPH) Drugs Product
12.5.3 Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue, Price and Gross Margin of ADC Therapeutics
12.6 Bayer HealthCare
12.6.1 Company profile
12.6.2 Representative Benign Prostatic Hyperplasia (BPH) Drugs Product
12.6.3 Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue, Price and Gross Margin of Bayer HealthCare
12.7 Bristol-Myers Squibb
12.7.1 Company profile
12.7.2 Representative Benign Prostatic Hyperplasia (BPH) Drugs Product
12.7.3 Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue, Price and Gross Margin of Bristol-Myers Squibb
12.8 Valeant Pharmaceuticals
12.8.1 Company profile
12.8.2 Representative Benign Prostatic Hyperplasia (BPH) Drugs Product
12.8.3 Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue, Price and Gross Margin of Valeant Pharmaceuticals
12.9 Endo Pharmaceuticals
12.9.1 Company profile
12.9.2 Representative Benign Prostatic Hyperplasia (BPH) Drugs Product
12.9.3 Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue, Price and Gross Margin of Endo Pharmaceuticals
12.10 Foresee Pharmaceuticals
12.10.1 Company profile
12.10.2 Representative Benign Prostatic Hyperplasia (BPH) Drugs Product
12.10.3 Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue, Price and Gross Margin of Foresee Pharmaceuticals
12.11 Madrigal Pharmaceuticals
12.11.1 Company profile
12.11.2 Representative Benign Prostatic Hyperplasia (BPH) Drugs Product
12.11.3 Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue, Price and Gross Margin of Madrigal Pharmaceuticals
12.12 Merck
12.12.1 Company profile
12.12.2 Representative Benign Prostatic Hyperplasia (BPH) Drugs Product
12.12.3 Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue, Price and Gross Margin of Merck
12.13 Novartis
12.13.1 Company profile
12.13.2 Representative Benign Prostatic Hyperplasia (BPH) Drugs Product
12.13.3 Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue, Price and Gross Margin of Novartis
12.14 Spectrum Pharmaceuticals
12.14.1 Company profile
12.14.2 Representative Benign Prostatic Hyperplasia (BPH) Drugs Product
12.14.3 Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue, Price and Gross Margin of Spectrum Pharmaceuticals
12.15 Takeda Pharmaceuticals
12.15.1 Company profile
12.15.2 Representative Benign Prostatic Hyperplasia (BPH) Drugs Product
12.15.3 Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue, Price and Gross Margin of Takeda Pharmaceuticals
12.16 Teva
12.17 Advaxis
12.18 ANI Pharmaceuticals
12.19 BHR Pharma
CHAPTER 13 UPSTREAM AND DOWNSTREAM MARKET ANALYSIS OF BENIGN PROSTATIC HYPERPLASIA (BPH) DRUGS
13.1 Industry Chain of Benign Prostatic Hyperplasia (BPH) Drugs
13.2 Upstream Market and Representative Companies Analysis
13.3 Downstream Market and Representative Companies Analysis
CHAPTER 14 COST AND GROSS MARGIN ANALYSIS OF BENIGN PROSTATIC HYPERPLASIA (BPH) DRUGS
14.1 Cost Structure Analysis of Benign Prostatic Hyperplasia (BPH) Drugs
14.2 Raw Materials Cost Analysis of Benign Prostatic Hyperplasia (BPH) Drugs
14.3 Labor Cost Analysis of Benign Prostatic Hyperplasia (BPH) Drugs
14.4 Manufacturing Expenses Analysis of Benign Prostatic Hyperplasia (BPH) Drugs
CHAPTER 15 REPORT CONCLUSION
CHAPTER 16 RESEARCH METHODOLOGY AND REFERENCE
16.1 Methodology/Research Approach
16.1.1 Research Programs/Design
16.1.2 Market Size Estimation
16.1.3 Market Breakdown and Data Triangulation
16.2 Data Source
16.2.1 Secondary Sources
16.2.2 Primary Sources
16.3 Reference
